Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
NCT07339059Phase 2Recruiting
- Start
- May 2026
- Primary completion
- Feb 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan in small cell lung cancer (SCLC). Started May 2026; status: recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07339059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07339059.